GM-CSF modulates autoantibody production and skin blistering in experimental epidermolysis bullosa acquisita

Journal of Immunology

Volumn 192, Issue 2, 2014, Pages 559-571

  Samavedam, Unni Krishna S R L ^a   Iwata, Hiroaki ^a   Müller, Susen ^a   Schulze, Franziska S ^a   Recke, Andreas ^a   Schmidt, Enno ^a   Zillikens, Detlef ^a   Ludwig, Ralf J ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; COLLAGEN TYPE 7; COMPLEMENT COMPONENT C3; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; REACTIVE OXYGEN METABOLITE;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; BLISTER; CLINICAL ARTICLE; COMPLEMENT DEPOSITION; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE SEVERITY; EPIDERMOLYSIS BULLOSA ACQUISITA; HUMAN; HUMAN CELL; IMMUNOGLOBULIN DEPOSITION; LEUKOCYTE ACTIVATION; LEUKOCYTE MIGRATION; MOUSE; NEUTROPHIL CHEMOTAXIS; NEUTROPHIL COUNT; NEUTROPHILIA; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; AUTOANTIBODIES; AUTOIMMUNE DISEASES; COLLAGEN TYPE VII; DISEASE MODELS, ANIMAL; EPIDERMOLYSIS BULLOSA ACQUISITA; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOGLOBULIN G; LYMPH NODES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEUTROPHILS; REACTIVE OXYGEN SPECIES; SKIN;

EID: 84892699070     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1301556     Document Type: Article

References (63)

1. Handman, E., and A. W. Burgess. 1979. Stimulation by granulocyte- macrophage colony-stimulating factor of Leishmania tropica killing by macrophages. J. Immunol. 122: 1134-1137. (Pubitemid 9150602)
2. Hamilton, J. A., E. R. Stanley, A. W. Burgess, and R. K. Shadduck. 1980. Stimulation of macrophage plasminogen activator activity by colony-stimulating factors. J. Cell. Physiol. 103: 435-445. (Pubitemid 11104577)
3. Cook, N., T. M. Dexter, B. I. Lord, E. J. J. Cragoe, Jr., and A. D. Whetton. 1989. Identification of a common signal associated with cellular proliferation stimulated by four haemopoietic growth factors in a highly enriched population of granulocyte/macrophage colony-forming cells. EMBO J. 8: 2967-2974. (Pubitemid 19274998)
4. Park, L. S., D. Friend, S. Gillis, and D. L. Urdal. 1986. Characterization of the cell surface receptor for granulocyte-macrophage colony-stimulating factor. J. Biol. Chem. 261: 4177-4183. (Pubitemid 17198855)
5. Griffin, J. D., S. A. Cannistra, R. Sullivan, G. D. Demetri, T. J. Ernst, and Y. Kanakura. 1990. The biology of GM-CSF: regulation of production and interaction with its receptor. Int. J. Cell Cloning 8(Suppl. 1): 35-44, discussion 44-45.
6. Metcalf, D. 1993. Hematopoietic regulators: redundancy or subtlety? Blood 82: 3515-3523. (Pubitemid 24006029)
7. Atkinson, Y. H., A. F. Lopez, W. A. Marasco, C. M. Lucas, G. G. Wong, G. F. Burns, and M. A. Vadas. 1988. Recombinant human granulocytemacrophage colony-stimulating factor (rH GM-CSF) regulates f Met-Leu-Phe receptors on human neutrophils. Immunology 64: 519-525.
8. Hamilton, J. A., D. S. Piccoli, J. Cebon, J. E. Layton, P. Rathanaswani, S. R. McColl, and T. Leizer. 1992. Cytokine regulation of colony-stimulating factor (CSF) production in cultured human synovial fibroblasts. II. Similarities and differences in the control of interleukin-1 induction of granulocytemacrophage CSF and granulocyte-CSF production. Blood 79: 1413-1419.
9. Gomez-Cambronero, J., J. Horn, C. C. Paul, and M. A. Baumann. 2003. Granulocyte-macrophage colony-stimulating factor is a chemoattractant cytokine for human neutrophils: involvement of the ribosomal p70 S6 kinase signaling pathway. J. Immunol. 171: 6846-6855. (Pubitemid 37532120)
10. Campbell, I. K., A. Bendele, D. A. Smith, and J. A. Hamilton. 1997. Granulocyte-macrophage colony stimulating factor exacerbates collagen induced arthritis in mice. Ann. Rheum. Dis. 56: 364-368. (Pubitemid 27305424)
11. Campbell, I. K., M. J. Rich, R. J. Bischof, A. R. Dunn, D. Grail, and J. A. Hamilton. 1998. Protection from collagen-induced arthritis in granulocytemacrophage colony-stimulating factor-deficient mice. J. Immunol. 161: 3639-3644.
12. Cook, A. D., E. L. Braine, I. K. Campbell, M. J. Rich, and J. A. Hamilton. 2001. Blockade of collagen-induced arthritis post-onset by antibody to granulocytemacrophage colony-stimulating factor (GM-CSF): requirement for GM-CSF in the effector phase of disease. Arthritis Res. 3: 293-298. (Pubitemid 32821522)
13. Plater-Zyberk, C., L. A. Joosten, M. M. Helsen, J. Hepp, P. A. Baeuerle, and W. B. van den Berg. 2007. GM-CSF neutralisation suppresses inflammation and protects cartilage in acute streptococcal cell wall arthritis of mice. Ann. Rheum. Dis. 66: 452-457. (Pubitemid 46580463)
14. Codarri, L., G. Gyülvészi, V. Tosevski, L. Hesske, A. Fontana, L. Magnenat, T. Suter, and B. Becher. 2011. RORγt drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation. Nat. Immunol. 12: 560-567.
15. Schön, M., D. Denzer, R. C. Kubitza, T. Ruzicka, and M. P. Schön. 2000. Critical role of neutrophils for the generation of psoriasiform skin lesions in flaky skin mice. J. Invest. Dermatol. 114: 976-983. (Pubitemid 30252720)
16. Kitching, A. R., X. Ru Huang, A. L. Turner, P. G. Tipping, A. R. Dunn, and S. R. Holdsworth. 2002. The requirement for granulocyte-macrophage colonystimulating factor and granulocyte colony-stimulating factor in leukocytemediated immune glomerular injury. J. Am. Soc. Nephrol. 13: 350-358. (Pubitemid 34106276)
17. Kondo, S., S. Pastore, G. M. Shivji, R. C. McKenzie, and D. N. Sauder. 1994. Characterization of epidermal cytokine profiles in sensitization and elicitation phases of allergic contact dermatitis as well as irritant contact dermatitis in mouse skin. Lymphokine Cytokine Res. 13: 367-375.
18. Gillessen, S., N. Mach, C. Small, M. Mihm, and G. Dranoff. 2001. Overlapping roles for granulocyte-macrophage colony-stimulating factor and interleukin-3 in eosinophil homeostasis and contact hypersensitivity. Blood 97: 922-928. (Pubitemid 32154275)
19. Sainathan, S. K., E. M. Hanna, Q. Gong, K. S. Bishnupuri, Q. Luo, M. Colonna, F. V. White, E. Croze, C. Houchen, S. Anant, and B. K. Dieckgraefe. 2008. Granulocyte macrophage colony-stimulating factor ameliorates DSS-induced experimental colitis. Inflamm. Bowel Dis. 14: 88-99. (Pubitemid 351196873)
20. Korzenik, J. R., B. K. Dieckgraefe, J. F. Valentine, D. F. Hausman, and M. J. Gilbert; Sargramostim in Crohn's Disease Study Group. 2005. Sargramostim for active Crohn's disease. N. Engl. J. Med. 352: 2193-2201. (Pubitemid 40727086)
21. Chen, Q., F. He, J. Kwang, J. K. Chan, and J. Chen. 2012. GM-CSF and IL-4 stimulate antibody responses in humanized mice by promoting T, B, and dendritic cell maturation. J. Immunol. 189: 5223-5229.
22. Puga, I., M. Cols, C. M. Barra, B. He, L. Cassis, M. Gentile, L. Comerma, A. Chorny, M. Shan, W. Xu, et al. 2012. B cell-helper neutrophils stimulate the diversification and production of immunoglobulin in the marginal zone of the spleen. Nat. Immunol. 13: 170-180.
23. Sitaru, C., A. Kromminga, T. Hashimoto, E. B. Bröcker, and D. Zillikens. 2002. Autoantibodies to type VII collagen mediate Fcgamma-dependent neutrophil activation and induce dermal-epidermal separation in cryosections of human skin. Am. J. Pathol. 161: 301-311. (Pubitemid 34760796)
24. Sitaru, C., S. Mihai, C. Otto, M. T. Chiriac, I. Hausser, B. Dotterweich, H. Saito, C. Rose, A. Ishiko, and D. Zillikens. 2005. Induction of dermal-epidermal separation in mice by passive transfer of antibodies specific to type VII collagen. J. Clin. Invest. 115: 870-878. (Pubitemid 40489391)
25. Woodley, D. T., R. Ram, A. Doostan, P. Bandyopadhyay, Y. Huang, J. Remington, Y. Hou, D. R. Keene, Z. Liu, and M. Chen. 2006. Induction of epidermolysis bullosa acquisita in mice by passive transfer of autoantibodies from patients. J. Invest. Dermatol. 126: 1323-1330. (Pubitemid 43997915)
26. Ward, J. C., J. B. Gitlin, D. J. Garry, A. Jatoi, S. D. Luikart, B. D. Zelickson, M. V. Dahl, and K. M. Skubitz. 1992. Epidermolysis bullosa acquisita induced by GM-CSF: a role for eosinophils in treatment-related toxicity. Br. J. Haematol. 81: 27-32.
27. Woodley, D. T., R. A. Briggaman, E. J. O'Keefe, A. O. Inman, L. L. Queen, and W. R. Gammon. 1984. Identification of the skin basement-membrane autoantigen in epidermolysis bullosa acquisita. N. Engl. J. Med. 310: 1007-1013. (Pubitemid 14129233)
28. Woodley, D. T., R. E. Burgeson, G. Lunstrum, L. Bruckner-Tuderman, M. J. Reese, and R. A. Briggaman. 1988. Epidermolysis bullosa acquisita antigen is the globular carboxyl terminus of type VII procollagen. J. Clin. Invest. 81: 683-687. (Pubitemid 18079715)
29. Ishii, N., T. Hamada, T. Dainichi, T. Karashima, T. Nakama, S. Yasumoto, D. Zillikens, and T. Hashimoto. 2010. Epidermolysis bullosa acquisita: what's new? J. Dermatol. 37: 220-230.
30. Ludwig, R. J., and D. Zillikens. 2011. Pathogenesis of epidermolysis bullosa acquisita. Dermatol. Clin. 29: 493-501, xi.
31. Gupta, R., D. T. Woodley, and M. Chen. 2012. Epidermolysis bullosa acquisita. Clin. Dermatol. 30: 60-69.
32. Huffman, J. A., W. M. Hull, G. Dranoff, R. C. Mulligan, and J. A. Whitsett. 1996. Pulmonary epithelial cell expression of GM-CSF corrects the alveolar proteinosis in GM-CSF-deficient mice. J. Clin. Invest. 97: 649-655. (Pubitemid 26057082)
33. Iwata, H., K. Bieber, B. Tiburzy, N. Chrobok, K. Kalies, A. Shimizu, S. Leineweber, A. Ishiko, A. Vorobyev, D. Zillikens, et al. 2013. B cells, dendritic cells, and macrophages are required to induce an autoreactive CD4 helper T cell response in experimental epidermolysis bullosa acquisita. J. Immunol. 191: 2978-2988.
34. Ishii, N., A. Recke, S. Mihai, M. Hirose, T. Hashimoto, D. Zillikens, and R. J. Ludwig. 2011. Autoantibody-induced intestinal inflammation and weight loss in experimental epidermolysis bullosa acquisita. J. Pathol. 224: 234-244.
35. Ludwig, R. J., T. M. Zollner, S. Santoso, K. Hardt, J. Gille, H. Baatz, P. S. Johann, J. Pfeffer, H. H. Radeke, M. P. Schön, et al. 2005. Junctional adhesion molecules (JAM)-B and-C contribute to leukocyte extravasation to the skin and mediate cutaneous inflammation. J. Invest. Dermatol. 125: 969-976.
36. Kasperkiewicz, M., R. Müller, R. Manz, M. Magens, C. M. Hammers, C. Somlai, J. Westermann, E. Schmidt, D. Zillikens, R. J. Ludwig, and A. Orosz. 2011. Heat-shock protein 90 inhibition in autoimmunity to type VII collagen: evidence that nonmalignant plasma cells are not therapeutic targets. Blood 117: 6135-6142.
37. Yu, X., K. Holdorf, B. Kasper, D. Zillikens, R. J. Ludwig, and F. Petersen. 2010. FcγRIIA and FcγRIIIB are required for autoantibody-induced tissue damage in experimental human models of bullous pemphigoid. J. Invest. Dermatol. 130: 2841-2844.
38. Recke, A., C. Sitaru, G. Vidarsson, M. Evensen, M. T. Chiriac, R. J. Ludwig, and D. Zillikens. 2010. Pathogenicity of IgG subclass autoantibodies to type VII collagen: induction of dermal-epidermal separation. J. Autoimmun. 34: 435-444.
39. Daley, J. M., A. A. Thomay, M. D. Connolly, J. S. Reichner, and J. E. Albina. 2008. Use of Ly6G-specific monoclonal antibody to deplete neutrophils in mice. J. Leukoc. Biol. 83: 64-70.
40. Samavedam, U. K., K. Kalies, J. Scheller, H. Sadeghi, Y. Gupta, M. F. Jonkman, E. Schmidt, J. Westermann, D. Zillikens, S. Rose-John, and R. J. Ludwig. 2013. Recombinant IL-6 treatment protects mice from organ specific autoimmune disease by IL-6 classical signalling-dependent IL-1ra induction. J. Autoimmun. 40: 74-85.
41. Chiriac, M. T., J. Roesler, A. Sindrilaru, K. Scharffetter-Kochanek, D. Zillikens, and C. Sitaru. 2007. NADPH oxidase is required for neutrophil-dependent autoantibody-induced tissue damage. J. Pathol. 212: 56-65. (Pubitemid 46746290)
42. Weisbart, R. H., L. Kwan, D. W. Golde, and J. C. Gasson. 1987. Human GMCSF primes neutrophils for enhanced oxidative metabolism in response to the major physiological chemoattractants. Blood 69: 18-21. (Pubitemid 17007069)
43. Tiburzy, B., M. Szyska, H. Iwata, N. Chrobok, U. Kulkarni, M. Hirose, R.J. Ludwig, K. Kalies, J. Westermann, D. Wong, and R.A. Manz. Persistent autoantibodyproduction by intermediates between short-and long-lived plasma cells in inflamed lymph nodes of experimental epidermolysis bullosa acquisita. PLOS One. In press.
44. Kasperkiewicz, M., M. Hirose, A. Recke, E. Schmidt, D. Zillikens, and R. J. Ludwig. 2010. Clearance rates of circulating and tissue-bound autoantibodies to type VII collagen in experimental epidermolysis bullosa acquisita. Br. J. Dermatol. 162: 1064-1070.
45. Radeke, H. H., R. J. Ludwig, and W. H. Boehncke. 2005. Experimental approaches to lymphocyte migration in dermatology in vitro and in vivo. Exp. Dermatol. 14: 641-666. (Pubitemid 41150361)
46. Shimanovich, I., S. Mihai, G. J. Oostingh, T. T. Ilenchuk, E. B. Bröcker, G. Opdenakker, D. Zillikens, and C. Sitaru. 2004. Granulocyte-derived elastase and gelatinase B are required for dermal-epidermal separation induced by autoantibodies from patients with epidermolysis bullosa acquisita and bullous pemphigoid. J. Pathol. 204: 519-527. (Pubitemid 39585950)
47. Roberts, A. W. 2005. G-CSF: a key regulator of neutrophil production, but that's not all! Growth Factors 23: 33-41. (Pubitemid 41656869)
48. Spitzer, G., D. Adkins, M. Mathews, W. Velasquez, C. Bowers, F. Dunphy, N. Kronmueller, R. Niemeyer, W. McIntyre, and P. Petruska. 1997. Randomized comparison of G-CSF + GM-CSF vs G-CSF alone for mobilization of peripheral blood stem cells: effects on hematopoietic recovery after high-dose chemotherapy. Bone Marrow Transplant. 20: 921-930. (Pubitemid 27510954)
49. Cairo, M. S., C. van de Ven, C. Toy, D. Mauss, and L. Sender. 1989. Recombinant human granulocyte-macrophage colony-stimulating factor primes neonatal granulocytes for enhanced oxidative metabolism and chemotaxis. Pediatr. Res. 26: 395-399. (Pubitemid 19267284)
50. Barker, J. N., M. L. Jones, R. S. Mitra, E. Crockett-Torabe, J. C. Fantone, S. L. Kunkel, J. S. Warren, V. M. Dixit, and B. J. Nickoloff. 1991. Modulation of keratinocyte-derived interleukin-8 which is chemotactic for neutrophils and T lymphocytes. Am. J. Pathol. 139: 869-876.
51. Yang, C. H., and E. R. Umamue. 2013. Neutrophils control the magnitude and spread of the immune response in a thromboxane A2-mediated process. J. Exp. Med. 210: 375-387.
52. Kasperkiewicz, M., and D. Zillikens. 2007. The pathophysiology of bullous pemphigoid. Clin. Rev. Allergy Immunol. 33: 67-77. (Pubitemid 351514141)
53. Bach, J. F. 2002. The effect of infections on susceptibility to autoimmune and allergic diseases. N. Engl. J. Med. 347: 911-920.
54. Langan, S. M., L. Smeeth, R. Hubbard, K. M. Fleming, C. J. Smith, and J. West. 2008. Bullous pemphigoid and pemphigus vulgaris-incidence and mortality in the UK: population based cohort study. BMJ 337: a180.
55. Joly, P., J. C. Roujeau, J. Benichou, C. Picard, B. Dreno, E. Delaporte, L. Vaillant, M. D'Incan, P. Plantin, C. Bedane, et al; Bullous Diseases French Study Group. 2002. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N. Engl. J. Med. 346: 321-327. (Pubitemid 34438839)
56. Joly, P., J. C. Roujeau, J. Benichou, E. Delaporte, M. D'Incan, B. Dreno, C. Bedane, A. Sparsa, I. Gorin, C. Picard, et al. 2009. A comparison of two regimens of topical corticosteroids in the treatment of patients with bullous pemphigoid: a multicenter randomized study. J. Invest. Dermatol. 129: 1681-1687.
57. Kuemmerle-Deschner, J. B., P. N. Tyrrell, I. Koetter, H. Wittkowski, A. Bialkowski, N. Tzaribachev, P. Lohse, A. Koitchev, C. Deuter, D. Foell, and S. M. Benseler. 2011. Efficacy and safety of anakinra therapy in pediatric and adult patients with the autoinflammatory Muckle-Wells syndrome. Arthritis Rheum. 63: 840-849.
58. Lovell, D. J., N. Ruperto, S. Goodman, A. Reiff, L. Jung, K. Jarosova, D. Nemcova, R. Mouy, C. Sandborg, J. Bohnsack, et al; Pediatric Rheumatology Collaborative Study Group; Pediatric Rheumatology International Trials Organisation. 2008. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N. Engl. J. Med. 359: 810-820.
59. Elliott, M. J., R. N. Maini, M. Feldmann, J. R. Kalden, C. Antoni, J. S. Smolen, B. Leeb, F. C. Breedveld, J. D. Macfarlane, H. Bijl, et al. 1994. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 344: 1105-1110. (Pubitemid 24317629)
60. Mease, P. J., B. S. Goffe, J. Metz, A. VanderStoep, B. Finck, and D. J. Burge. 2000. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 356: 385-390. (Pubitemid 30487495)
61. Sandborn, W. J., P. Rutgeerts, R. Enns, S. B. Hanauer, J. F. Colombel, R. Panaccione, G. D'Haens, J. Li, M. R. Rosenfeld, J. D. Kent, and P. F. Pollack. 2007. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann. Intern. Med. 146: 829-838. (Pubitemid 351650483)
62. Ludwig, R. J., and E. Schmidt. 2009. Cytokines in autoimmune bullous skin diseases. Epiphenomena or contribution to pathogenesis? G. Ital. Dermatol. Venereol. 144: 339-349.
63. Ludwig, R. J., K. Kalies, J. Köhl, D. Zillikens, and E. Schmidt. 2013. Emerging treatments for pemphigoid diseases. Trends Mol. Med. 19: 501-512.